Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
- Interim data from Phase II Study of Zandelisib shows 75.4% ORR in Japanese patients…